Cargando...
TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
BACKGROUND: Cardiotoxicity in the form of cardiac arrhythmia, myocardial infarction, and angina-like symptoms are not rare complications of fluoropyrimidines as 5-Fluorouracil (5FU) and capecitabine. DISCUSSION: Tas-102, a novel oral fluoropyrimidine, was recently approved by FDA for the treatment o...
Guardado en:
| Publicado en: | BMC Cancer |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4932685/ https://ncbi.nlm.nih.gov/pubmed/27377645 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2409-8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|